WuXi Biologics has once again raised the bar for sustainability and transparency. The global biotech powerhouse has been honored with the Hong Kong ESG Reporting Awards (HERA) 2025 for Outstanding ESG Disclosure, marking a major milestone in its commitment to openness and accountability.

 

This latest recognition follows last year’s ESG Report Benchmark Award from HERA, underscoring the consistency of WuXi Biologics’ forward-looking ESG efforts. Beyond regulatory compliance, the company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide.

 

In today’s competitive business landscape, transparent ESG disclosure is more than a reporting requirement—it’s a differentiator. WuXi Biologics provides detailed updates on sustainability initiatives, including corporate governance, talent development, and GHG emission reduction, assuring stakeholders that the company is driving meaningful change in Green CRDMO.

 

“Transparency is the cornerstone of trust. We firmly believe that openly sharing our ESG journey is essential, because only through collaboration can we help to create lasting value that contributes positively to society and the environment. 

 

"Receiving the ESG Disclosure Award not only validates our efforts, but also inspires us to continue raising the bar as we lead the industry toward a more responsible and sustainable future,” said Dr Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee.